Receipt of live, attenuated vaccine within 30 days prior to the first dose of investigational treatment; Note: patients, if enrolled, should not receive live vaccine during the study and up to 30 days after the last dose of investigational treatment
Receipt of a live vaccine within 30 days prior to registration for protocol therapy
Receipt of a live, attenuated vaccine within 4 weeks prior to randomization, during treatment, or within 5 months following the last dose of atezolizumab/placebo
Receipt of live vaccine within 28 days of planned first dose of TVEC
Receipt of a live virus vaccine within 28 days prior to Day 1 of Cycle 1
Receipt of a live vaccine within 30 days of start of study treatment
Receipt of a live virus vaccine within 28 days prior to Day 1 of Cycle 1
Receipt of live attenuated vaccine within 30 days prior to the first dose of study drug. Note: Patients, if enrolled, should not receive live vaccine whilst receiving study treatment and up to 30 days after the last dose of study treatment.
Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. Note: Subjects, if enrolled, should not receive live vaccine whilst receiving IP and up to 30 days after the last dose of IP.
Receipt of attenuated vaccine within 2 weeks prior to starting study treatment.
Receipt of a live vaccine =< 30 days prior to registration
Receipt of live attenuated vaccine within 30 days before the first dose of study treatment
Receipt of live attenuated vaccination within 30 days prior to the first dose of IP; Note: Patients, if enrolled, should not receive live vaccine during the study and up to 30 days after the last dose of IP
Receipt of live attenuated vaccine within 28 calendar days prior to the first study treatment is NOT permitted
Receipt of live attenuated vaccination within 30 days prior the first dose of durvalumab (NOTE: If a vaccine is part of the treatment regimen for the indication under study, the vaccine is permitted)
Receipt of live attenuated vaccine within 30 days prior to study entry; enrolled patients should not receive live vaccine during the study and 30 days after the last dose of durvalumab
Receipt of a live vaccine within 30 days of receipt of study therapy
Receipt of a live virus vaccine =< 2 months prior to registration
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab (e.g. live attenuated influenza vaccine [LAIV], measles/mumps/rubella vaccine [MMR], variola virus vaccine [VAR], zoster, yellow fever, etc.)
Receipt of live, attenuated vaccine within 28 days prior to the first dose of investigational products (NOTE: Subjects, if enrolled, should not receive live vaccine during the study and 180 days after the last dose of investigational products)
Receipt of live, attenuated vaccine within 28 days prior to the first dose of durvalumab and tremelimumab (NOTE: subjects, if enrolled, should not receive live vaccine during the study and for 180 days after the last dose of both drugs)
Receipt of a live/attenuated vaccine within 6 weeks prior to the screening visit.
Receipt of a live vaccine within 30 days of study entry
Receipt of live, attenuated vaccine within 28 days prior to the first dose of durvalumab (Note: enrolled patients should not receive live vaccine during the study and for 180 days after the last dose of durvalumab)
Receipt of a live, attenuated vaccine within 28 days prior to the first dose of MEDI4736 and tremelimumab (NOTE: subjects, if enrolled, should not receive live vaccine during the study or for 180 days after the last dose of both drugs)
Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. Note: Patients, if enrolled, should not receive live vaccine during the study and up to 30 days after the last dose of IP.
Receipt of live or live attenuated vaccine within 12 weeks prior to enrollment
Receipt of live vaccine within 30 days prior to the first dose of trial treatment
Receipt of any live vaccine within 4 weeks.
Receipt of live attenuated vaccine within 30 days prior to the first dose of investigational treatment; Note: patients, if enrolled, should not receive live vaccine during the study and up to 30 days after the last dose of investigational treatment
Receipt of live attenuated vaccine within 30 days prior to the first dose of study drugs; Note: Patients, if enrolled, should not receive live vaccine whilst receiving treatment with study drugs and up to 90 days after the last dose of study drugs
Receipt of live, attenuated vaccine within 30 days prior to study entry or the first dose of MEDI0457.\r\n* Note: patients, if enrolled, should not receive live vaccine during the study and up to 30 days after the last dose of IP.
Receipt of live, attenuated vaccine within 30 days prior to the first dose of durvalumab
Receipt of live, attenuated vaccine within 28 days prior to the first dose of investigational product
Receipt of live, attenuated vaccine within 30 days prior to the first dose of IP (NOTE: Subjects, if enrolled, should not receive live vaccine during the study and for 30 days after the last dose of durvalumab).
Receipt of a live vaccine within 30 days before the first dose of study treatment.
Receipt of a live vaccine within 4 weeks prior to rituximab administration
Receipt of a live attenuated vaccine within 4 weeks prior to study drug
Receipt of live attenuated vaccine within 30 days prior to the first dose of IP
Receipt of live, attenuated vaccine within 30 days prior to the first dose of MEDI4736
Receipt of live, attenuated vaccine within 30 days prior to the first dose of Investigational Product;
Receipt of live, attenuated vaccine within 28 days prior to the first dose of investigational products )
Receipt of live, attenuated vaccine within 30 days prior to the first dose of MEDI4736
Receipt of a live vaccine within 30 days of receipt of study therapy
Receipt of a live (attenuated) vaccine within 1 month prior to Screening
Receipt of a live virus vaccine within 28 days prior to Day 1 of Cycle 1
Receipt of a live vaccine within 30 days of receipt of study therapy
No receipt of a live vaccine within 4 weeks prior to registration
Chemotherapy or any other investigational agents within 14 days of first receipt of study treatment, or major surgery within 28 days of first receipt of study treatment, or palliative radiation within 7 days of first receipt of study treatment
Receipt of live vaccine within 4 weeks prior to study drug administration
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab; for example, the intramuscular influenza vaccine can be administered but the intranasal vaccine is a live attenuated virus that cannot be given
Receipt of any live vaccine within 4 weeks prior to first dose of study treatment.
Receipt of live attenuated vaccination within 30 days prior to the first vaccine
